Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Schips, L; Augustin, H; Zigeuner, RE; Gallé, G; Habermann, H; Trummer, H; Pummer, K; Hubmer, G.
Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?
Urology. 2002; 59(2):220-223
Doi: 10.1016%2FS0090-4295%2801%2901522-9
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Schips Luigi
- Co-Autor*innen der Med Uni Graz
- Augustin Herbert
- Habermann Helga
- Hubmer Gerhart
- Pummer Karl
- Zigeuner Richard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVES: To assess the value of repeated transurethral resection (TUR) in patients with newly diagnosed superficial bladder cancer. METHODS: A second TUR was performed in 110 consecutive patients (24 women and 86 men) with newly diagnosed superficial bladder cancer. The mean age was 66 years (range 30 to 85). A second TUR was performed within 4 to 6 weeks after the initial TUR. After the first TUR, the pathologic stage was pTa in 31 patients (28%), pT1 in 76 (70%), and carcinoma in situ in 3 (2%). The pathologic records of the second TUR were reviewed and compared with the findings of the first operation. RESULTS: Cystoscopy before the second TUR was negative in 79 patients. Of these cases, 14 (17.7%) had cancer histologically. The second TUR was negative in 70 patients (63.6%). Twenty-two (20%) had residual cancer of the same stage, 9 (8.2%) had a lower stage, and 9 (8.2%) had a higher stage. Of 31 patients with Stage pTa and 76 patients with Stage pT1 at the first TUR, 19 (61.3%) and 51 (67.1%) had a negative second TUR, respectively. CONCLUSIONS: We recommend a second TUR for patients with superficial bladder cancer for several reasons. A negative second TUR provides important prognostic information. In addition, removal of residual cancer is achieved early. Finally, patients with pT1 G3 tumors are at high risk of residual, or even invasive, cancer and should be offered definitive therapy as early as possible.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Carcinoma in Situ - diagnosis
- Diagnosis, Differential - diagnosis
- Female - diagnosis
- Humans - diagnosis
- Male - diagnosis
- Middle Aged - diagnosis
- Neoplasm Recurrence, Local - diagnosis
- Neoplasm Staging - diagnosis
- Neoplasm, Residual - diagnosis
- Reoperation - diagnosis
- Retrospective Studies - diagnosis
- Transurethral Resection of Prostate - diagnosis
- Urinary Bladder Neoplasms - diagnosis